Opinion|Videos|January 31, 2025
Where Are We Going? Future Perspectives on Navigating the Treatment Paradigm in Transplant-Eligible NDMM
Panelists discuss how the evolving treatment landscape for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM) is being shaped by emerging data on optimal treatment sequencing strategies, both in frontline settings and subsequent lines of therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- As treatments continue to evolve, how do you see the future treatment landscape changing for patients with transplant-eligible NDMM?
- How do the data inform your consideration of treatment sequencing beyond the front line?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5